Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has announced a strategic refocusing of its research and development portfolio following the expiration and termination of its option and license arrangements with PinCell S.r.l. related to the PC111 program. The decision, effective Aug. 31, was not driven by any new negative scientific findings regarding PC111, according to the company. Instead, it allows Scinai to concentrate its R&D resources on its proprietary NanoAb platform while preserving capital and management capacity for its contract development and manufacturing organization (CDMO) business.
The company is advancing two IL-17 programs within the NanoAb platform, including an intradermal psoriasis program for which approximately €12 million in grant financing is under evaluation in Poland. This focus on the NanoAb platform is expected to streamline operations and potentially accelerate the development of these promising therapeutic candidates.
In addition to the R&D refocus, Scinai reported approximately $3.1 million in committed CDMO customer orders as of Aug. 16. The company continues to pursue approximately $5 million in CDMO revenue for 2026, subject to project execution, timing, revenue recognition, and additional business opportunities. These figures underscore the growth potential of Scinai's CDMO segment, which is expected to benefit from the company's strategic shift.
The termination of the PinCell agreement and the subsequent refocusing of the R&D portfolio represent a significant move for Scinai as it aims to strengthen its financial position and operational efficiency. By dedicating more resources to its NanoAb platform and CDMO services, the company is positioning itself for long-term growth in the biopharmaceutical industry.
Scinai Immunotherapeutics is a biopharmaceutical company focused on developing innovative immunology therapies. The company's pipeline includes therapeutic candidates licensed from the Max Planck Society and formerly from PinCell S.r.l. Additionally, Scinai owns Scinai Biopharma Services Ltd., a CDMO that provides development and manufacturing services to biotechnology and pharmaceutical companies through facilities in Jerusalem and Yavne, Israel.
Investors and industry observers will be watching closely to see how this strategic refocusing impacts Scinai's future development and financial performance. The company's commitment to its NanoAb platform and CDMO growth could yield significant benefits as it navigates the competitive landscape of immunology therapeutics.
For more information on Scinai Immunotherapeutics and its latest developments, visit the company's newsroom at https://ibn.fm/SCNI.
